Emerging Therapies in Respiratory Tract Infections: Current Advances and Future Perspectives


{@post_title}







{
“@context”: “https://schema.org”,
“@type”: “ScholarlyArticle”,
“headline”: “{@post_title}”,
“author”: [
{
“@type”: “Person”,
“name”: “{@coauthors}”
}
],
“keywords”: “{@keywords}”,
“description”: “{@post_excerpt}”,
“datePublished”: “2024-08-05”,
“dateModified”: “2024-08-05”,
“publisher”: {
“@type”: “Organization”,
“name”: “{@publisher_name}”
},
“url”: “{@html_link}”,
“sameAs”: “{@pdf_link_}”,
“isPartOf”: {
“@type”: “PublicationIssue”,
“issueNumber”: “{@journal_issue}”,
“isPartOf”: {
“@type”: “PublicationVolume”,
“volumeNumber”:”{@journal_volume}”,
“isPartOf”: {
“@type”: “Periodical”,
“name”: “{@journal_name}”
}
}
},
“pageStart”: “110”,
“pageEnd”: “125”
}

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 02 | 02 | Page :
    By

    Abhishek Kumar,

  • Pankaj Chasta,

  • Kamalesh Mistry,

  1. Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh,Rajasthan, India
  2. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh,Rajasthan, India
  3. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh,Rajasthan, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_201069’);});Edit Abstract & Keyword

The impact of respiratory tract infections (RTI) as a global public health problem continues to be high morbidity and mortality rates. The development of novel therapeutic approaches stemmed from the fact that conventional treatment strategies, antibiotics, antivirals, antifungals etc. have become increasingly ineffective because of rise of antimicrobial resistance (AMR). Next generation therapies, such as novel antimicrobial agents, host directed therapies and novel drug delivery systems have come on the stage by recent development in biotechnology and nanomedicine. Respiratory pathogens have demonstrated promising efficacy through the emergence or the pursuit of mRNA based antivirals, CRISPR-based gene editing and monoclonal antibodies. Inhalable nanocarriers, liposomal formulations, and bioengineered hydrogels improved drug targeting and bioavailability, and provided site specific treatment with minimal systemic toxicity. Besides that, gene therapy and RNA based therapeutics including siRNA, antisense oligonucleotides have also further expanded treatable entity for chronic RTIs. Nevertheless, efforts will have to be made to overcome regulatory hurdles, ethical concerns and clinical translation barriers before the adoption is widespread. Furthermore, artificial intelligence and big data analytics are benefiting to optimize the treatment strategies and thus to follow the personalized medicine. This review covers in a comprehensive manner recently developed drugs for RTI management including innovative drug delivery systems, gene-based therapeutics and host directed therapies. Integrating multidisciplinary approaches at the early stage for overcoming resistance mechanisms and to develop more effective and personalized interventions is the future of RTI treatment.

Keywords: Respiratory Tract Infections, Antimicrobial Resistance, Gene Therapy, Nanomedicine, RNA-Based Therapeutics, Inhalable Drug Delivery

How to cite this article:
Abhishek Kumar, Pankaj Chasta, Kamalesh Mistry. Emerging Therapies in Respiratory Tract Infections: Current Advances and Future Perspectives. Recent Trends in Infectious Diseases. 2025; 02(02):-.
How to cite this URL:
Abhishek Kumar, Pankaj Chasta, Kamalesh Mistry. Emerging Therapies in Respiratory Tract Infections: Current Advances and Future Perspectives. Recent Trends in Infectious Diseases. 2025; 02(02):-. Available from: https://journals.stmjournals.com/rtid/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_201069’);});Edit

References

  1. World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023.
  2. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance; 2016.
  3. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277–83.
  4. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science. 2009;325(5944):1089–93.
  5. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–8.
  6. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med. 2013;368(4):299–302.
  7. Nelson RE, Hatfield KM, Wolford H, Samore MH, Scott RD II, Reddy SC, et al. National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clin Infect Dis. 2021;72(Suppl 1):S17–26.
  8. Chen H, Wichterle H, Arlotta P. Molecular regulation of antiviral response in respiratory epithelial cells. J Clin Invest. 2022;132(1):e145527.
  9. Tängdén T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment, and infection control. J Intern Med. 2015;277(5):501–12.
  10. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomized controlled trials. Lancet. 2015;385(9979):1729–37.
  11. Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368(6498):1499–504.
  12. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79.
  13. Geller BL, Marshall-Batty K, Schnell FJ, McKnight MM, Iversen PL, Greenberg DE. Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo. J Infect Dis. 2013;208(10):1553–60.
  14. Tan J, Gu W, Xu Q, Heng BC, Chen X. Nanotechnology in respiratory disease treatment. Expert Opin Drug Deliv. 2021;18(2):187–204.
  15. Carvalho TC, Peters JI, Williams RO III. Influence of particle size on regional lung deposition – what evidence is there? Int J Pharm. 2011;406(1–2):1–10.
  16. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–24.
  17. Lee J, Yoon SR, Nam YS. Bioengineered polymeric hydrogels for advanced drug delivery systems. Pharmaceutics. 2020;12(8):685.
  18. Han X, Xu Y, Zhang Y, Liu J. CRISPR/Cas systems and their applications in diagnosis and therapy of infectious diseases. Front Cell Infect Microbiol. 2020;10:573905.
  19. Tong Y, Huang J, Wang Y, Ma Q, Chen H, Wang A. Applications of CRISPR-Cas system in respiratory infectious diseases. J Med Virol. 2021;93(7):3780–9.
  20. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16(4):343–53.
  21. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.
  22. Li H, Limenitakis JP, Greiff V, Yilmaz B, Schären OP, Urbaniak C, et al. Mucosal or systemic microbiota exposures shape the B cell repertoire. Nature. 2020;584(7820):274–8.
  23. Gollwitzer ES, Marsland BJ. Microbiota abnormalities in inflammatory airway diseases – potential for therapy. Pharmacol Ther. 2014;141(1):32–9.
  24. Man WH, de Steenhuijsen Piters WA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017;15(5):259–70.
  25. Ray P, Dittel BN. Interrelatedness between dysbiosis in the gut microbiota due to antibiotic treatment and gastrointestinal tract immune responses. Microorganisms. 2020;8(3):394.
  26. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010;11(1):69–86.
  27. Yuan Y, Gao M. Jumbo bacteriophages: an overview. Front Microbiol. 2017;8:403.
  28. Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162–73.
  29. Langel SN, Johnson S, Martinez CI, Tedjakusuma SN, Peinovich N, Dora EG, et al. Oral and intranasal vaccines: current progress and challenges in respiratory infectious diseases. Vaccine. 2022;40(23):3319–31.
  30. Rello J, Pérez M, Roca O. Sepsis and the respiratory system. Curr Opin Crit Care. 2021;27(1):13–9.
  31. Dheda K, Limberis JD, Pietersen E, Meintjes G, Theron G, Dorman SE, et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients in rural South Africa: a prospective cohort study. Lancet Respir Med. 2017;5(4):269–81.
  32. Ginsburg AS, Klugman KP. COVID-19 pneumonia and the appropriate use of antibiotics. Lancet Glob Health. 2020;8(12):e1453–4.
  33. Cilloniz C, Dominedò C, Garcia-Vidal C, Torres A. Community-acquired pneumonia as an emergency condition. Curr Opin Crit Care. 2018;24(6):531–9.
  34. Baidya D, Das D, Maity S. Applications of big data in infectious disease research: promises and challenges. Infect Dis Model. 2022;7(1):1–13.
  35. Deo RC. Machine learning in medicine. Circulation. 2015;132(20):1920–30.
  36. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.
  37. Rengasamy KR, Venkatesan A, Rajagopal K. Personalized medicine in respiratory tract infections: current status and future directions. Lung India. 2022;39(1):29–36.
  38. Ghosh S, Ghosh R, Das S. Synthetic biology in antimicrobial resistance: a prospective therapeutic solution. Curr Opin Biotechnol. 2021;69:180–9.
  39. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis. 2016;16(2):239–51.
  40. Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. 2020;5(7):644–5.
  41. Xie Y, Bergström A, van de Wiele T, Norder Grusell E, Arike L, Ottosson F, et al. Persistence of gut mucosa-associated bacteria in the human gastrointestinal tract after oral consumption: a randomized, double-blind, placebo-controlled pilot study. Lancet Microbe. 2021;2(5):e219–29.
  42. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008;47(S1):S3–13.
  43. Shafiek H, Lee CS, Berry D. Role of inhaled therapy in chronic respiratory tract infections. Respir Med. 2021;187:106552.
  44. Halstead SB. Critique of World Health Organization recommendations for treatment of dengue fever. Clin Infect Dis. 2007;45(8):1093–7.
  45. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019. Lancet. 2020;396(10258):1204–22.
  46. MacIntyre CR, Wang Q. Physical distancing, face masks, and eye protection for prevention of COVID-19. Lancet. 2020;395(10242):1950–1.
  47. Hamer DH, Holmgren J, Clements ML. Mucosal immunization of humans with Vibrio cholerae whole-cell vaccine induces antigen-specific IgA in the respiratory tract. Vaccine. 1989;7(5):443–6.
  48. Shah NS, Auld SC, Brust JCM, Mathema B, Ismail N, Moodley P, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med. 2017;376(3):243–53.
  49. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323(8):709–10.
  50. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–33.
Ahead of Print Subscription Review Article
Volume 02
02
Received 10/04/2025
Accepted 26/07/2025
Published 30/07/2025
Publication Time 111 Days
85

[first_name] [last_name]

My IP

PlumX Metrics